SCOTT THACHER, CEO TO SPEAK AT UPCOMING 17th ANNUAL SAN DIEGO MEDCHEM SYMPOSIUM
Orphagen CEO, Scott Thacher, will speak tomorrow at the 17th Annual San Diego MedChem Syposium at UC San Diego Price Center Theatre. His presentation is entitled “First-in-Class Drug Discovery at Unexplored Orphan Nuclear Receptors.” The objective of this one-day...
Orphagen Pharmaceuticals presents pharmacology of steroidogenic factor-1 antagonists at the Endocrine Society’s 95th Annual Meeting
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, presented a late-breaking poster describing the effect of antagonists to steroidogenic factor-1 (SF-1) on adrenal synthesis of glucocorticoids at the Endocrine Society’s 95th Annual Meeting in...
Orphagen Pharmaceuticals Awarded $446,635 to Investigate Novel Small Molecules to Treat Retinitis Pigmentosa
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) has awarded the company $446,635 under the Small Business Innovative Research...
Orphagen Pharmaceuticals Awarded US Patent for modulators of orphan nuclear receptor ROR-gamma
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that it has been awarded US patent 8,389,739 for modulators of retinoid-related orphan receptor gamma (RORγ). The patent is Orphagen’s first in the RORγ field and describes several...
Gönül Veliçelebi joins the Orphagen Board of Directors
Orphagen Pharmaceuticals announced today that Gönül Veliçelebi, Founder and CEO of CalciMedica, has been appointed to the Board of Directors. “Dr. Veliçelebi’s extensive experience in drug discovery and development, entrepreneurism and corporate strategy will be...
Orphagen Pharmaceuticals Featured on Frontpage of BioWorld Today for Novel Approach to Drug Discovery
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, was recently profiled on the front page of BioWorld Today. A featured article on Orphagen Pharmaceuticals, titled “Orphagen Seeks Ligands for Orphan Nuclear Receptors”, highlighted the...
Orphagen Pharmaceuticals Awarded Phase I SBIR Grant for $220,839 for Investigation of Novel Therapeutic Class to Treat Endometriosis
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, announced today that the National Institutes of Health has awarded the Company $220,839 in funding through the Small Business Innovative Research (SBIR) program. The Phase I grant is designed...
Orphagen Pharmaceuticals Awarded $622,971 in Qualifying Therapeutic Discovery Project (QTDP) Program Grants
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, announced today that a total of $622,971 in grants was awarded under the Qualifying Therapeutic Discovery Project (QTDP) program provided for in the Health Care and Education Reconciliation...
Orphagen Pharmaceuticals Awarded Federal Grant for Adrenocortical and Prostate Cancer
Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of small molecule drugs for the treatment of adrenocortical and prostate cancer. The objective of the...
Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
Orphagen Pharmaceuticals announced today that it has been awarded a two year federal grant to further characterize a novel class of small molecule drugs with potential to treat circadian rhythm sleep disorders and more serious psychiatric illnesses, such as anxiety,...